July 8th, 2025 | 07:05 CEST
Rheinmetall above EUR 2,000? Bayer shares exhausted? NetraMark Holdings with lots of upside potential!
It seems only a matter of time before Rheinmetall shares break through the EUR 2,000 barrier. Increasingly, analysts are setting price targets above this mark. And operations are running smoothly, as demonstrated by the latest ammunition order and the Company's participation in the German government's billion-euro investment program. NetraMark, on the other hand, does not have to invest billions in research and development. The AI specialist is still an insider tip. However, the first study is now available, and analysts anticipate over 50% upside potential. In contrast, analysts see the end of the price fireworks at Bayer. Are they right?
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
RHEINMETALL AG | DE0007030009 , BAYER AG NA O.N. | DE000BAY0017 , NETRAMARK HOLDINGS INC | CA64119M1059
Table of contents:
"[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
NetraMark Holdings: More than 50% upside potential
Pharmaceutical and biotech companies can save billions in the development of new drugs with NetraMark Holdings' artificial intelligence. The Canadian software company aims to make clinical trials more efficient, accurate, and regulatory compliant through AI-powered analytics. The Company is still something of an insider tip. But now the first analyst research is available.
The experts at Zacks Small-Cap Research took a closer look at NetraMark. The result is clear: the analysts see the fair value of NetraMark shares at CAD 2.25. The stock is currently trading at CAD 1.35. According to Zacks, this means that the AI specialist has upside potential of over 50%.
The analysts highlighted that NetraMark signed a global agreement with CRO Worldwide Clinical Trials in April 2025. The contract research organization conducts clinical trials for pharmaceutical and biotech companies worldwide. Within the partnership, Worldwide offers its customers the NetraAI platform for optimizing trials. In addition, NetraMark already has several medium-sized pharmaceutical companies as customers and has reported a growing pipeline of leads.
Overall, the Company is addressing a huge market. McKinsey estimates that the pharmaceutical industry spent around USD 247 billion on research and development in 2022. The potential savings through AI are correspondingly large.
Bayer: Is the price potential exhausted?
Bayer would certainly also benefit from NetraMark's services. On the one hand, the Leverkusen-based company urgently needs to fill its product pipeline in the pharmaceutical sector. On the other hand, its coffers are pretty empty due to years of legal proceedings.
Despite the problems, the share has performed well in recent months and is currently trading at EUR 26. The gain for the current year is an impressive 34%.
Yesterday, however, JPMorgan poured cold water on the price rally. Analysts confirmed their price target of EUR 25 for Bayer shares. Due to the lack of upside potential, they rate the stock as "Neutral." Analysts do not expect any surprises from the upcoming quarterly figures. Bayer has announced its Q2 report for August 6.
Goldman Sachs is more optimistic about Bayer shares. Analysts recommend the DAX stock as a "Buy" with a price target of EUR 34.
Rheinmetall: When will the EUR 2,000 mark be broken?
It seems only a matter of time before Rheinmetall shares break through the EUR 2,000 barrier. Increasingly, analysts are setting price targets above this mark. UBS and Hauck & Aufhäuser Lampe believe that shares in Germany's largest defense company could reach EUR 2,200. JPMorgan and Italy's Mediobanca have even set price targets of EUR 2,250.
As is well known, Rheinmetall's operations are running smoothly. The arms manufacturer can look forward to a considerable share of the EUR 25 billion in investments announced by the German government for tanks. Orders for ammunition are also pouring in at a rapid pace. Rheinmetall recently announced that a European NATO country has signed a multi-year contract for the delivery of 155mm artillery ammunition.
The volume for Assegai-family projectiles and propellant charges amounts to several million euros. Deliveries are scheduled to be completed by the end of 2027. Rheinmetall also announced that it is investing heavily in expanding its production capacities in order to meet the growing demand for 155 mm ammunition and propellants.
Pharmaceutical companies need to reduce their research and development costs. NetraMark offers a proven AI platform for this purpose. The stock is likely to become more widely known in the second half of the year and emerge from the slumber of recent weeks. In addition, takeover speculation is likely to increase. Rheinmetall remains a core investment in the defense sector. Its valuation of over EUR 81 billion is certainly not cheap, but the momentum is continuing. At Bayer, the ongoing legal proceedings should not be ignored.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
